Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01624766 · ClinicalTrials.gov registry record · Phase 1
Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 57
- Enrollment target
NCT01624766: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT01624766 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 57 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01624766, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 57 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of everolimus when given together with anakinra or denosumab in treating participants with cancers that have spread to other places in the body and have come back or aren't responding to treatment. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Anakinra is designated to block a protein that is involved in tumor development, new blood vessels growing, and the spread of cancer. Monoclonal antibodies, such as denosumab, may interfere with the ability of tumor cells to grow and spread. Giving everolimus and anakinra or denosumab may work better in treating participants with advanced cancers.
Interventions
- DRUG Everolimus
- BIOLOGICAL Denosumab
- BIOLOGICAL Anakinra
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2012-06-19 |
| Est. Completion | 2021-02-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01624766
The ClinicalTrials.gov registry entry for NCT01624766 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Everolimus is the first listed.
NCT01624766 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01624766 about?
NCT01624766 is a clinical study titled "Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers". This phase I trial studies the side effects and best dose of everolimus when given together with anakinra or denosumab in treating participants with cancers that have spread to other places in the body and have come back or aren't responding to treatment. Everolimus may stop the growth of tumor cell...
What is the current status of trial NCT01624766?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2012-06-19. Estimated completion is 2021-02-24.
What interventions are being tested in trial NCT01624766?
The interventions under investigation include: Everolimus (DRUG), Denosumab (BIOLOGICAL), Anakinra (BIOLOGICAL).
Who is sponsoring clinical trial NCT01624766?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.